Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
Revenue
Fate Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fate Therapeutics Inc
NASDAQ:FATE
|
Revenue
$63.5m
|
CAGR 3-Years
26%
|
CAGR 5-Years
68%
|
CAGR 10-Years
52%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Fate Therapeutics Inc's Revenue?
Revenue
63.5m
USD
Based on the financial report for Dec 31, 2023, Fate Therapeutics Inc's Revenue amounts to 63.5m USD.
What is Fate Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
52%
Over the last year, the Revenue growth was -34%. The average annual Revenue growth rates for Fate Therapeutics Inc have been 26% over the past three years , 68% over the past five years , and 52% over the past ten years .